Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, provides an overview of companion diagnostics.

Diagnostics provide the foundation of care, Lazarus says, and companion diagnostics are no exception. Ten years ago, 5-10% of drugs in the pipeline had a corresponding biomarker – today, up to 45% of drugs do.

Companion diagnostics allow clinicians to select the group of patients that will most likely respond to that drug. New drugs, Lazarus says, often have a better safety profile compared with older drugs but must be used selectively due to cost and other factors.

Tadd Lazarus, MD

Articles

Dr. Lazarus Discusses Companion Diagnostics